• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Portage Biotech Inc.

    8/1/25 5:24:39 PM ET
    $PRTG
    Oil & Gas Production
    Energy
    Get the next $PRTG alert in real time by email
    S-8 1 fs8_073125.htm FORM S-8

    As filed with the Securities and Exchange Commission on August 1, 2025

     

    Registration No. 333-             

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    PORTAGE BIOTECH INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

    British Virgin Islands   Not Applicable
    (State or Other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification No.)
    Clarence Thomas Building, P.O. Box 4649
    Road Town, Tortola
    British Virgin Islands
      VG1110
    (Address of Principal Executive Offices)   (Area Code)

     

    Portage Biotech Inc. Amended and Restated 2021 Equity Incentive Plan

    (Full Title of the Plan)

     

    Andrea Park, CFO

    c/o Portage Development Services, Inc.

    1111B S Governors Ave, Ste 25907

    Dove, Delaware, 19904

    (Name and Address of Agent For Service)

     

    (302) 219-5556
    (Telephone Number, Including Area Code, of Agent For Service)

     

    With Copies to:

     

    Steven J. Abrams, Esq.

    Hogan Lovells US LLP

    1735 Market Street, Suite 2300

    Philadelphia, PA 19103

    Telephone (267) 675-4600

    Michael Doyle

    Forbes Hare LLP

    5 King’s Bench Walk

    Temple, London EC4Y 7DN

    United Kingdom

    Telephone +44 (0) 207 0143 225

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer   ☒   Smaller reporting company ☐
        Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 is being filed by Portage Biotech Inc., a company registered in the British Virgin Islands (the “Registrant”), to register 197,743 ordinary shares of the Registrant, no par value per share (the “Ordinary Shares”), issuable under the Registrant’s Amended and Restated 2021 Equity Incentive Plan, as amended (the “2021 Plan”).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    As permitted by the rules of the Securities and Exchange Commission (the “Commission”), this registration statement on Form S-8 omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the 2021 Plan covered by this registration statement as required by Rule 428(b)(1) under the Securities Act of 1933 (the “Securities Act”).

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.Incorporation of Documents by Reference.

     

    The following documents of the Registrant filed with the Commission are incorporated by reference in this registration statement as of their respective dates:

     

    (a)the Registrant’s Annual Report on Form 20-F for the fiscal year ended March 31, 2025 filed with the Commission on July 25, 2025;

     

    (b)the Registrant’s Reports on Form 6-K filed with or furnished to the Commission on April 28, 2025, May 29, 2025, June 9, 2025, June 25, 2025, and June 27, 2025; and

     

    (c)the description of the Registrant’s Ordinary Shares contained in its registration statement on Form 8-A filed with the Commission on February 18, 2021, as updated by Exhibit 2.1 to the Registrant’s Annual Report on Form 20-F for the fiscal year ended March 31, 2022 filed with the Commission on August 1, 2022, and any amendment or report filed for the purpose of further updating that description.

     

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), including (i) any future annual reports on Form 20-F and (ii) any future reports on Form 6-K that are identified in such reports as being incorporated by reference in this registration statement (but only to the extent identified in such report), but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the Commission.

     

    For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 4.Description of Securities.

     

    Not applicable.

     

    Item 5.Interests of Named Experts and Counsel.

     

    Not applicable.

     

     

     

     

    Item 6.Indemnification of Directors and Officers.

     

    British Virgin Islands law does not limit the extent to which a company’s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the British Virgin Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. In addition, a company may only indemnify a person who acted honestly and in good faith and in what he or she believed to be in the best interests of the company, and in the case of criminal proceedings, the person had no reasonable cause to believe that his or her conduct was unlawful.

     

    The Registrant’s Memorandum and Articles of Association provides that the Registrant may indemnify its directors, officers, agents or its liquidator (each an “Indemnifiable Person”) against all expenses, including legal fees, and against all judgments, fines and amounts paid in settlement and reasonably incurred in connection with legal, administrative or investigative proceedings if such Indemnifiable Person is or was a party or is threatened to be a party to proceedings by virtue of the fact he or she is or was a director, officer, agent or liquidator of the Registrant or is or was at the request of the Registrant serving as a director, officer, agent or liquidator or in another capacity for another entity The Registrant may only indemnify an Indemnifiable Person if he or she acted honestly and in good faith with a view to the Registrant’s best interests and, with respect to any criminal action, he or she must have had no reasonable cause to believe his or her conduct was unlawful.

     

    The Registrant may purchase and maintain insurance in relation to any person who is or was a director, or who at the request of the Registrant is or was serving as a director of, or in any other capacity is or was acting for another body corporate or a partnership, joint venture, trust or other enterprise, against any liability asserted against the person and incurred by the person in that capacity, whether or not the Registrant has or would have had the power to indemnify the person against the liability. The Registrant currently maintains director and officer insurance.

     

    Item 7.Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

     

     

     

     

    Item 8.Exhibits.

     

    Exhibit
    Number
      Description
    4.1   Amended and Restated Memorandum of Association and Articles of Association of Portage Biotech Inc. as filed in the British Virgin Island on September 22, 2022 – Incorporated herein by reference to Exhibit 4.1 to Form 6-K filed on September 22, 2022.
    4.2   Portage Biotech Inc. Amended and Restated 2021 Equity Incentive Plan - Incorporated herein by reference to Exhibit 4.2 to Form S-8 filed on December 1, 2023.
    4.3*   Amendment No. 1 to Portage Biotech Inc. Amended and Restated 2021 Equity Incentive Plan.
    5.1*   Opinion of Forbes Hare LLP.
    23.1*   Consent of Marcum LLP.
    23.2* Consent of CBIZ CPAs P.C.
    23.3*   Consent of Forbes Hare LLP (included in Exhibit 5.1).
    24.1*   Power of Attorney (included on signature page).
    107*   Filing Fee Table.

     

    *Filed herewith.

     

     

     

     

     

     

     

     

     

     

     

     

     

    Item 9.Undertakings.

     

    (a)       The undersigned Registrant hereby undertakes:

     

    (1)       To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)       To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)      To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment hereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and

     

    (iii)       To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

    (2)       That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)       To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)       The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)       Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tortola, British Virgin Islands, on August 1, 2025.

     

      PORTAGE BIOTECH INC.
       
      By: /s/ Alexander Pickett
      Name: Alexander Pickett
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Alexander Pickett and Andrea Park, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Name   Title   Date
             
    /s/ Alexander Pickett   Chief Executive Officer and Director   August 1, 2025
    Alexander Pickett   (Principal Executive Officer)    
             
    /s/ Andrea Park   Chief Financial Officer   August 1, 2025
    Andrea Park   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Justin Stebbing   Chairman of the Board   August 1, 2025
    Justin Stebbing        
             
    /s/ Gregory Bailey   Director   August 1, 2025
    Gregory Bailey        
             
    /s/ James Mellon   Director   August 1, 2025
    James Mellon        
             
    /s/ Jean-Christophe Renondin   Director   August 1, 2025
    Jean-Christophe Renondin        
             
    /s/ Steven Mintz   Director   August 1, 2025
    Steven Mintz        

     

     

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the requirements of the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of the Registrant, has signed this registration statement on August 1, 2025.

     

         
      By:   /s/ Alexander Pickett
          Alexander Pickett
          Chief Executive Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $PRTG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTG

    DatePrice TargetRatingAnalyst
    7/18/2022$26.00Outperform
    Oppenheimer
    3/7/2022$32.00Buy
    HC Wainwright & Co.
    9/21/2021$30.00Outperform
    Oppenheimer
    9/2/2021$40.00Buy
    B. Riley Securities
    8/19/2021$35.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PRTG
    SEC Filings

    View All

    SEC Form S-8 filed by Portage Biotech Inc.

    S-8 - PORTAGE BIOTECH INC. (0001095435) (Filer)

    8/1/25 5:24:39 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    SEC Form 424B3 filed by Portage Biotech Inc.

    424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)

    7/28/25 9:00:38 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    SEC Form 424B3 filed by Portage Biotech Inc.

    424B3 - PORTAGE BIOTECH INC. (0001095435) (Filer)

    7/25/25 4:31:04 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    $PRTG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

    DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended March 31, 2025. Financial Results from Year Ended March 31, 2025 The Company incurred a net loss of approximately $6.8 million during the fiscal year ended March 31, 2025 ("Fiscal 2025"), which includes approximately $0.2 million of net non-cash expenses. This compares to a net loss of approximately $75.4 million during the fiscal

    7/25/25 4:15:33 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

    DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands ("Portage"), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system's ability to fight cancer. For more information, visit www.portagebiotech.com. Forward-Looki

    6/25/25 7:00:11 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    Portage Biotech and Compedica Stock-for-Stock Exchange

    DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands ("Portage") announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man ("Compedica") entered a mutual Subscription Agreement ("Subscription Agreement"). Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,165,501 shares of Compedica with a value of $4.29 per share, in a transaction valued at $5,000,000. After the transaction, Compedica will own 27.4% of the issued and outstanding o

    6/9/25 6:00:41 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    $PRTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Portage Biotech Inc.

    SC 13G/A - PORTAGE BIOTECH INC. (0001095435) (Subject)

    11/14/24 4:26:22 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    Amendment: SEC Form SC 13D/A filed by Portage Biotech Inc.

    SC 13D/A - PORTAGE BIOTECH INC. (0001095435) (Subject)

    11/14/24 4:07:02 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    SEC Form SC 13G filed by Portage Biotech Inc.

    SC 13G - PORTAGE BIOTECH INC. (0001095435) (Subject)

    2/14/24 3:50:16 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    $PRTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Portage Biotech with a new price target

    Oppenheimer resumed coverage of Portage Biotech with a rating of Outperform and set a new price target of $26.00

    7/18/22 9:02:05 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    HC Wainwright & Co. initiated coverage on Portage Biotech with a new price target

    HC Wainwright & Co. initiated coverage of Portage Biotech with a rating of Buy and set a new price target of $32.00

    3/7/22 6:24:57 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    Oppenheimer initiated coverage on Portage Biotech with a new price target

    Oppenheimer initiated coverage of Portage Biotech with a rating of Outperform and set a new price target of $30.00

    9/21/21 4:56:17 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    $PRTG
    Leadership Updates

    Live Leadership Updates

    View All

    Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

    WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed Chief Executive Officer of the subsidiary, to be named Cyncado TherapeuticsTM, Inc. As CEO, Mr. Molloy will lead efforts to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A2a and A2b receptor antagonists. These therapeutics are distin

    1/6/25 5:00:49 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    $PRTG
    Financials

    Live finance-specific insights

    View All

    Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

    WESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company has acquired the outstanding ownership interest (approximately 22%) of its invariant natural killer T cell (iNKT agonist) platform and now fully owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3. The platform was acquired through Portage's iOx Therapeutics Ltd. (iOx) subsidiary from the founding equity holders in exchange for 1,070,000 ordinary shares of P

    7/20/22 9:00:00 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

    Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at OrbiMed, to join the Portage Board of Directors Enters into committed share purchase agreement with Lincoln Park Capital to purchase ordinary shares of Portage for up to $30 Million; proceeds to potentially extend cash runway for current projects into 2024 Management to host a conference call and webcast Thursday, July 7 at 8:30am ET to discuss the adenosine programs and combined pipeline in greater detail WESTPORT, Conn., July 06, 2022 (GLOBE NEWSWIRE) -- Portage

    7/6/22 4:05:00 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

    WESTPORT, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended December 31, 2021 (the "third quarter"). "During the third quarter and in recent weeks we've taken steps to accelerate our lead programs for PORT-2 and PORT-3, investigating options to expand our clinical sites beyond our current footprint and finding the means of accelerating patient enrollment," said Dr. Ian Walters, chief executive officer of Portage. "Wi

    2/24/22 5:43:17 PM ET
    $PRTG
    Oil & Gas Production
    Energy